Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 33c, Beats on Revenue; Offers FY24 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. SPCX
6. NVDA
7. PRIM
8. META
9. SPY
10. DPZ

Go back to Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 33c, Beats on Revenue; Offers FY24 Revenue Guidance

Catalyst Pharmaceutical Partners (CPRX) PT Raised to $31 at Citi

August 9, 2024 4:56 AM EDT

Citi analyst Samantha Semenkow raised the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $31.00 (from $27.00) while maintaining a Buy rating.

The analyst comments "There was a lot to like in Catalysts 2Q print, as we outlined in our initial take, with... More